Connect with us

Snow Software Research Finds Workers Go Around IT Just So They Can Do Their Job

Published

on

Reading Time: 4 minutes

Both the youngest and the most influential employees are emotionally
invested in work applications, highlighting why organizations must
change their approach to technology

STOCKHOLM & AUSTIN, Texas–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ITAssetManagement?src=hash” target=”_blank”gt;#ITAssetManagementlt;/agt;–The majority of global workers are going rogue with work devices,
software and applications despite being aware of the potential business
risks involved, according to new research released by Snow
Software
, the global leader in technology intelligence solutions.
The study, which polled 3,000 professionals in the United States, Europe
and Asia Pacific, finds stark
contrasts between the mindset of today’s workers and the priorities of
IT leaders.
This rift was especially notable in younger employees,
who represent the future of the workforce. In fact, millennials
are almost twice as likely to go behind IT’s back
compared to older
workers, with 81% admitting they have used or accessed something on
their work device without permission versus just 51% of baby boomers who
have done the same.

“There is a tectonic shift happening in the enterprise, driven by a
rapid move to the cloud and nearly unlimited access to technology,” said
Vishal Rao, President & Chief Executive Officer at Snow. “Part of what
we see in this data is a philosophical evolution in what the future of
work looks like. The CIO and their teams are now strategic business
partners with the power to fundamentally change their organizations.
That new role requires empowering a new generation of employees and
enabling the business to be as effective as possible while also
balancing financial, regulatory and compliance risks.”

When it comes to unsanctioned device behavior, many workers are breaking
the rules in an effort to get their job done – 41% of global employees
report using professional software or applications on their work device
without IT’s permission. That makes it the second most common
infraction, behind the 46% who access personal documents but ahead of
other popular personal content like apps, music, videos and photos. When
asked about the impact of needing IT’s permission to get software or
applications to do their job, 40% of workers reported that they feel
watched, 32% said that it slowed them down and impacted deadlines, 27%
said it was frustrating and 26% felt it negatively impacted productivity.

As one manager put it, while it wasn’t the case for them, needing IT’s
permission to get work software and applications “would definitely make
me feel all of the above. I would also feel that the business was
micromanaged, that they didn’t really respect or appreciate their
associates and that they need to get up to speed with the direction that
businesses are moving in.”

Additional key findings include:

  • When it came to generational differences in work device behavior, the
    biggest disparity was in software and applications – in the millennial
    age group, 47% reported accessing work apps and 46% admitted to
    accessing personal apps on their work device without permission,
    compared to just 22% and 18% of boomers respectively.
  • Younger workers are exponentially more emotional when they do ask for
    permission to acquire software or applications. Compared to baby
    boomers, millennials are nearly five times more likely to be nervous
    (24% vs 5%) and over four times more likely to feel it is beneath them
    (22% vs 5%).
  • In general, management-level employees (manager, director, vice
    president or executive) were almost twice as likely to use
    unauthorized professional or personal software and applications
    compared to individual contributors (entry-level, associate or
    specialist).
  • Vice presidents and C-level executives led the way in using work apps
    (57%) and personal apps (51%) on their work device without permission.
  • There is a disconnect between workers’ behavior and understanding the
    business risks of unsanctioned and unmanaged technology. For example,
    just 7% of executives said they don’t think it causes any business
    issues, yet 57% have engaged in that exact behavior by downloading
    work applications and software without IT’s permission. And even
    though entry-level employees are the best behaved, with only 25%
    downloading work software or applications without permission, they
    were also most likely to think that doing so doesn’t have any negative
    impact on the business.

These findings further validate the challenges organizations face as
digitally-native employees and business unit leaders – not IT
gatekeepers – increasingly drive the investment and consumption of
software, applications and services. Today’s businesses and institutions
need to understand what is in their technology landscape as well as how
it is being used. But the real opportunity lies in using those insights
to maximize value and drive better outcomes. This evolution was the
driving force behind Snow’s newly expanded mission: to provide complete
insight and manageability across all technology.

“In an era defined by digital transformation, we are focused on helping
the enterprise face some of their biggest challenges,” said Vishal Rao,
President & CEO of Snow. “The market has shifted away from niche point
solutions that each manage a different part of your cloud, software and
hardware. Our focus is on providing a single platform that goes beyond
discovering assets to driving action. From the Fortune 100 to federal
agencies, from Stockholm to San Francisco to Sydney, we are helping the
world’s most impactful organizations gain complete technology
intelligence.”

Underlying Snow’s mission is a foundation of customer-centricity,
highlighted by the recent appointment of Richard Anderson as the
industry’s first Chief Customer Officer
. End-users themselves
recognized the company as a 2019
Gartner Peer Insights Customer’s Choice for Software Asset Management
.
Analysts also named Snow a Leader in the 2019
Gartner Magic Quadrant for Software Asset Management
for the second
year in a row, placing it furthest to the right for completeness of
vision.

About Snow Software
Snow Software is the global leader in
technology intelligence solutions, ensuring the trillions spent on all
forms of technology is optimized to drive maximum value. More than 4,000
organizations around the world rely on Snow’s platform to provide
complete visibility, optimize usage and spend, and minimize regulatory
risk. Headquartered in Stockholm, Snow has more local offices and
regional support centers than any other software asset and cloud
management provider, delivering unparalleled results to our customers
and partners. To find out more about Snow Software, visit www.snowsoftware.com.

For the latest information about Snow, please visit:

Web: www.snowsoftware.com
Twitter:
@snowsoftware

Contacts

Julie Neumann
Snow Software
julie.neumann@snowsoftware.com
+1
615 498 9650

Cannabis

One Year of Medical Cannabis in the UK, Data by Grow Biotech

Published

on

Photo source: southeusummit.com

 

The 1st of November 2019 will mark the one year anniversary of the legalisation of medical cannabis in the United Kingdom. A year after Charlotte Caldwell’s tireless campaign to obtain life-saving medication for her son Billy catapulted medical cannabis onto the public agenda, the cost of prescriptions has dropped substantially while the number of scripts written has increased, but more needs to be done before it can be more widely offered by the National Health Service (NHS).

The average price of a month’s supply of medical cannabis imported through Logist has dropped from £750 to £550, reducing the average monthly prescription cost by 27%, while the average price per gram has also fallen by 25%. The reduction in cost is a combination of increased volume (meaning the costs associated with importing products is lower per prescription) and the increased availability of different products.

The type of medical specialist consultants writing prescriptions for medical cannabis has also diversified to include pain, oncology and neurology. There has also been a broadening in the delivery method for medical cannabis requested by specialist consultants to include different cannabis oils, pills and flowers, which is largely a result of the greater range of products available. Since February, Logist has imported approximately 1.5kg of flower to the UK.

The vast majority of medical cannabis has made its way to the UK thanks to Logist, a joint-venture formed between specials importer IPS Pharma, and Grow Biotech, the UK’s leading medical cannabis market access specialists.

Timeline of Events

  • 1st November 2018 – New regulations introduced, which allowed for the import and prescription of cannabis-based medicines
  • 14 February 2019 – The first bulk import of medical cannabis in the UK and first patients to receive medication from Logist
  • May 2019 – EU based bio-pharmaceutical company MGC Pharma appoints Logist
  • August 2019 – NICE publish interim report on medical cannabis
  • August 2019 – American medical cannabis giant Columbia Care announces that it will fund and provide medicine for clinical trials in the UK
  • September 2019– Leading Canadian company Aurora appoints IPS Pharma and Grow Biotech as importer and distributor for the UK market
  • September 2019 – Medical cannabis consultant informs Logist that a patient is no longer using opioids to manage their condition following treatment with medical cannabis

Looking forward to the near future, Chief Operating Officer of Grow Biotech, Hari Guliani, said, “Over the next twelve months we expect the UK’s medical community as a whole to take on the challenge of understanding how cannabis might help their patients. We are expecting leading consultants to publish papers on the impact they have seen on their patients, as well as evidence gathered through MHRA-approved trials. This will significantly improve the data available to regulators, policymakers and NICE.”

At present, it is only available on the NHS in extremely limited circumstances and is only obtainable through a prescription written by a specialist consultant in the private sector. NICE (The National Institute of Health Care Excellence) has advised that more clinical trials need to be undertaken in the UK and overall costs of medication need to be reduced before medical cannabis can be prescribed by NHS consultants. However, new medical trials are now underway and prices associated with the import of medical cannabis are falling dramatically, giving hope to the thousands of patients who are still struggling to access life-changing medication.

Another major change which cannot be overlooked is funding for the UK’s young medical cannabis industry. Ben Langley, Chief Executive Officer of Grow Biotech explained that, “We have seen a massive increase in funding for UK businesses operating within the medical cannabis space, especially from North America. In addition to the £5m Grow Biotech has raised over the last two years, there have been notably well received fundraises for Emmac Life Sciences PLC (£11m raised in March 2019) and for Oxford Cannabinoid Therapeutics ($10m in April 2019). This trend is likely to accelerate as European medical cannabis gradually establishes itself as an attractive asset class for global capital and European equity exchanges start to open their doors to cannabis companies.

Both Ben Langley and Hari Guliani are available for comment and interview.

 

SOURCE Grow Biotech

Continue Reading

Cannabis

GNCC Capital, Inc. – Pending Transaction

Published

on

 

GNCC Capital, Inc. (OTC: GNCP) (“The Company” or “GNCC”) advises that the new Board of Directors is in the process of consummating a further transaction in the Cannabis Sector and in South Africa.

Given that this is a related party transaction; they are awaiting ratification from an Independent party.

Upon consummation of this transaction; the new GNCC Directors will actively engage with shareholders. This decision was taken given that this transaction materially affects the size and scope of the Company’s South African Cannabis interests.

We reiterate that both Ms. Allen and Mr. Cox have recognized the need to; and have committed to expend the next two to three weeks in shareholder engagement. This is to ensure that all shareholders and investors become familiar with the Company’s new business operations, opportunities, Licensing and the Cannabis Industry in South Africa.

Forward-Looking Statements:-This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings, which are on file with the OTC Markets Group.

SOURCE GNCC Capital, Inc.

Continue Reading

Cannabis

Empower Clinics Provides Corporate Updates Highlighting Triple Digit Patient Growth and Subsidiary Sun Valley Health Launches New Modalities and Patient Services

Published

on

 

EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce it is launching seven new modalities and services for patients in the Sun Valley Health clinics commencing Monday October 14th, 2019.

The Company also has patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 versus September 2018 with 614 patients seen.

“The tremendous year-over-year increase in patient visits is a testament to the operating strengths and patient management demonstrated by our clinic team members, each and every day,” said Steven McAuley, CEO of Empower. “Their passion for patient wellbeing and the use of numerous communication tools ensures world-class service is provided throughout the entire patient journey.”

As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services.

New Modalities and Services

  • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
  • CBD-Cannabis-Supplement Consumption & Coaching Consultation
  • Introduction to Alternative Health and Cannabinoid Therapies by a Physician
  • Comprehensive Naturopathic Patient Analysis & Consultation
  • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
  • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
  • Spectracell Micronutrient Test & Physician Consultation/Action Plan

“By offering our new suite of laboratory testing, alternative health consulting, and CBD therapies we are able to address the needs of our current patients and serve the community outside of cannabis that are seeking alternative health care,” states Dustin Klein, Director & VP Business Development. “Incorporating our new modalities, high quality vitamins, supplements, and CBD products into our network of clinics is a natural progression toward our goal of becoming the nation’s premier alternative healthcare provider.”

Additional UPDATES

  • New Modalities and Patient Services The Company continues to see patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 over July 2018 614 patients seen.

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com has been actively participating in various franchise and cannabis expos in St. LouisChicago and Houston to market the Sun Valley Health franchise program, attracting numerous qualified candidates for available territory locations. The Company has accepted many applications and has provided the Franchise Disclosure Document (FDD) to qualified applicants in anticipation of completing the first initial territory sales.

 

SOURCE Empower Clinics Inc.

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania